Latest Boardroom Shifts News

VDM Group remains suspended from ASX trading amid a legal dispute over its Angolan joint ventures, while pivoting towards new critical minerals opportunities in Australia.

Papyrus Australia appoints Daniel Schmidt as CEO to lead its transition from R&D to commercial operations, alongside a strategic restructure to support growth.

Finexia Financial Group has resumed trading following announcements of a significant business disposal and new executive appointments, signaling a pivotal restructuring phase.

Key Petroleum Limited has appointed Yan Zhao as Managing Director, bringing over two decades of mining and exploration expertise to the helm. The move signals potential strategic shifts amid a modest remuneration package.

IDT Australia announces the immediate resignation of CEO Paul McDonald, appointing Executive Chair Mark Simari to lead as the company reports a 40.6% revenue increase but a widening net loss for FY25.

360 Capital Mortgage REIT has confirmed comprehensive compliance with ASX corporate governance principles for FY2025, with a single noted exception regarding board chair independence.

Articore Group has appointed CEO Vivek Kumar as Managing Director, underscoring the board’s confidence following a record-breaking quarter and strategic turnaround efforts.

FirstWave’s Q4 FY25 update reveals a slight revenue decline but highlights a strategic AWS partnership and new chairman appointment, signaling a pivotal growth phase.

ChemX Materials Limited has explained the delayed filing of director interest notices, attributing it to transitional challenges during its recent recapitalisation and governance overhaul.

Platinum Capital Limited has pulled its proposed scheme of arrangement due to insufficient shareholder support but will proceed with an on-market buy-back. Meanwhile, L1 Capital pushes for management control and board renewal.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Vitrafy Life Sciences announces a leadership change with CEO Kate Munnings retiring and co-founder Brent Owens stepping up to lead the company’s next growth phase.